Drug Development · global
New heart failure drug tovinontrine shows a low-dose signal, but Phase 2 trials have yet to establish clinical benefit
The new PDE9-inhibiting therapy showed a trend toward lower biomarker levels on top of existing heart failure treatment, but the highest dose produced no clear improvement. These results have prompted researchers to explore lower doses, while leaving open whether efficacy can extend beyond blood test results.
The hurdle for a new heart failure drug is how much additional help it can provide to patients already receiving treatment. On October 11, Cardurion presented Phase 2 results for its oral drug tovinontrine (CRD-750) at the Heart Failure Society of America (HFSA) annual meeting: the two lower doses showed signals of reductions in a heart failure biomarker, while the highest dose showed no clear benefit. However, these changes do not yet establish that the drug can reduce hospitalizations or deaths.
Tovinontrine targets phosphodiesterase 9 (PDE9), seeking to enhance natriuretic peptide signaling within heart muscle cells. This pathway transmits signals through cyclic guanosine monophosphate (cGMP); inhibiting PDE9 is intended to allow those signals to persist. The studies also tracked NT-proBNP, using this blood biomarker to assess treatment response. But a gap remains between affecting a signaling pathway and delivering actual benefits to patients, and that gap requires further validation.
Cycle-1-REF was a randomized, double-blind, placebo-controlled trial that enrolled 529 patients with heart failure with reduced ejection fraction. In addition to their existing guideline-recommended treatment, participants received 2.5, 25, or 50 milligrams of tovinontrine twice daily, or placebo. The primary assessment was the change in NT-proBNP at week 12. According to HCPLive, the three dose groups included 53, 159, and 159 participants, respectively, while the placebo group included 158; the lowest-dose group had a substantially smaller sample.
The data also leave more room for caution than the company's positive framing suggests. The estimated changes in NT-proBNP listed by HCPLive were −14.1%, −10.8%, and −4.4%, from the lowest to the highest dose, with P values of 0.07, 0.05, and 0.45, respectively. The reported 95% confidence intervals for all three groups included zero, meaning the possibility of no difference still cannot be ruled out. Although the P value for the 25-milligram group was near the commonly used significance threshold, it would be inappropriate to claim on that basis that efficacy has been established.
Cycle-2-PEF, presented at the same meeting, made the limitations of the high dose clearer. This trial in heart failure with preserved ejection fraction assigned 277 participants to 50 milligrams of tovinontrine or placebo. HCPLive reported that median plasma cGMP increased by 40% in the drug group at week 12, yet NT-proBNP fell by only 1.7%, compared with a 10.1% decrease in the placebo group. Even with stronger biochemical signaling, the expected biomarker improvement did not follow.
The researchers therefore proposed a hypothesis: when cGMP rises beyond a certain level, the body may activate counter-regulation that weakens downstream signaling. Cardurion and trial investigator James Udelson believe this might explain why lower doses produced larger changes. However, this explanation comes from the trial results and post hoc analyses. It remains a hypothesis awaiting validation and cannot be regarded as a confirmed pharmacological mechanism. According to HCPLive, the team plans to launch the Phase 2b trial Cycle-3 in 2027 to further test lower doses in patients with reduced ejection fraction.
Cardurion said both trials showed good safety and tolerability, but its announcement did not provide a complete breakdown of adverse events, and short-term results are insufficient to answer questions about the risks of long-term use. Beyond identifying an appropriate dose, the next step requires stronger evidence of efficacy: whether reductions in NT-proBNP are accompanied by symptom improvement and ultimately translate into fewer hospitalizations or longer survival will determine whether this new mechanism can become a treatment option.